Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform

Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform

Welch, S. R., Spengler, J. R., Genzer, S. C., Chatterjee, P., Flint, M., Bergeron, É., ... & Spiropoulou, C. F.

Viruses 13.7 (2021): 1255.

Lujo virus (LUJV), a highly pathogenic arenavirus, was first identified in 2008 in Zambia. To aid the identification of effective therapeutics for LUJV, we developed a recombinant reporter virus system, confirming reporter LUJV comparability with wild-type virus and its utility in high-throughput antiviral screening assays. Using this system, we evaluated compounds with known and unknown efficacy against related arenaviruses, with the aim of identifying LUJV-specific and potential new pan-arenavirus antivirals. We identified six compounds demonstrating robust anti-LUJV activity, including several compounds with previously reported activity against other arenaviruses. These data provide critical evidence for developing broad-spectrum antivirals against high-consequence arenaviruses.


Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform

Products Recommended in this Publication

B0084-463609

Favipiravir

For research use only
B0084-061939

Deoxynojirimycin

For research use only
B0084-051542

Paliperidone

For research use only
936539-80-9

Betrixaban maleate

For research use only
B0084-057968

Lubiprostone

For research use only
91188-00-0

Merafloxacin

For research use only